General Updates

GLAND PHARMA LIMITED GLAND September 13, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor 25th floor, Dalal Street Plot no. C-1, Block G, Bandra Kurla Complex Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 543245 Symbol: GLAND (ISIN: INE068V01023) Dear Sir/Madam, Sub: Allotment of Equity Shares on exercise of Employee Stock Options This is to inform you that pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; the ESOP Compensation Committee of the Board of Directors of the Company in its meeting held on September 13, 2026, has allotted 42,393 (Forty Two Thousand Three Hundred and Ninety Three only) Equity shares of Re.1/- each of the Company, fully paid up, to 35 (Thirty Five only) employee(s) and 1,800 (One Thousand Eight Hundred only) Equity shares of Re.1/- each of the Company, fully paid up, to 01 (One only) employee on exercise of their Stock Options pursuant to Gland Pharma Employee Stock Options Scheme, 2025 (ESOP 2025) and Gland Pharma Limited Employee Stock Options Scheme, 2019 (ESOP 2019) respectively. Further the ESOP Compensation Committee has approved the formal closure and winding up of the Gland Pharma Limited Employee Stock Option Scheme, 2019 with immediate effect, as all eligible options have been fully exercised/lapsed and no further options remain available for grant under the said pool. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 165,010,854/- comprising 165,010,854 Equity shares of face value Re.1/- each. Further, please find enclosed the details as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. This is for your information and records. Yours truly, For Gland Pharma Limited Sampath Kumar Pallerlamudi Company Secretary & Compliance Officer Encl: As above Regd. Office: Corporate Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads Plot No. 11 & 84, TSIIC Phase: IV D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Pashamylaram (V), Patancheru (M), Sangareddy District Medchal-Malkajgiri District, Hyderabad 500043,Telangana, India Hyderabad 502307, Telangana, India Tel: +91-40-30510999 Fax: +91 0-30510800 Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLAND Continuation Sheet Details under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 S. Particulars 1 Company name and address of Registered Office: Gland Pharma Limited Sy. No. 143 - 148, 150 and 151, Near Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal, Dundigal - Gandimaisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India 2 Name of the recognised Stock Exchanges on which the Company's shares are listed: BSE Limited (Scrip Code: 543245) National Stock Exchange of India Limited (Symbol: GLAND) 3 Filing date of the statement referred in regulation 10(b) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognised Stock Exchange: ➢ ESOP 2019 - The Company was not a listed Company on the date of the Board Meeting for issuance of securities ➢ ESOP 2025 - BSE & NSE - May 03, 2025 4 Filing Number, if any: ➢ ESOP 2019 – Not Applicable ➢ ESOP 2025 - BSE – 231155; NSE – 48425 5 Title of the Scheme pursuant to which shares are issued, if any: Gland Pharma Limited Employee Stock Option Scheme 2019 & Gland Pharma Employee Stock Option Scheme 2025 6 Kind of security to be listed: Equity Shares 7 Par value of the shares: Rs. 1/- per share 8 Date of issue of shares: September 13, 2026 (Date of Allotment on Exercise) 9 Number of shares issued: ➢ ESOP 2019 - 1,800 equity shares ➢ ESOP 2025 - 42,393 equity shares 10 Share Certificate No., if applicable: Not Applicable GLAND Continuation Sheet 11 Distinctive number of the share, if applicable: 16,49,66,662 to 16,50,10,854 (both inclusive) 12 ISIN Number of the shares if issued in Demat: INE068V01023 13 Exercise price per share: ➢ 1,800 options at Rs. 542.- each under ESOP 2019 ➢ 24,529 options at Rs. 773.30/-each, 3,444 options at Rs. 937.20/-each and 14,420 options at Rs. 1/- each under ESOP 2025 14 Premium per share: ➢ Rs. 541/- for 1,800 options under ESOP 2019 ➢ Rs. 772.30/- for 24,529 options, Rs. 936.20/- for 3,444 options and NIL for 14,420 options under ESOP 2025 15 Total issued shares after this issue: 16,50,10,854 equity shares 16 Total issued share capital after this issue: Rs. 16,50,10,854/- 17 Details of any lock-in on the shares: Not Applicable 18 Date of expiry of lock-in: Not Applicable 19 Whether shares are identical in all respects to existing shares? If not, when will they become identical? Yes, the shares rank pari passu with the existing shares 20 Details of listing fees, if payable: Not Applicable